Music has been the driving force of the legendary Scottish author's career. At 66, he's releasing a new Trainspotting sequel ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Savers in Willowick is a bargain hunter’s paradise come to life. The store stands out with its bright red sign against the white building facade. Inside, you’ll discover a gigantic space bursting with ...

The Republican-led Senate rescued funding for PEPFAR in a package of spending cuts last month, but the HIV-prevention program ...

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

This story first appeared in the UNAIDS Global AIDS Update 2025 report.

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...